Research ArticleHIV

The human naive B cell repertoire contains distinct subclasses for a germline-targeting HIV-1 vaccine immunogen

See allHide authors and affiliations

Science Translational Medicine  04 Jul 2018:
Vol. 10, Issue 448, eaat0381
DOI: 10.1126/scitranslmed.aat0381

Learning from naive B cells

Despite decades of intensive research, HIV vaccines are unable to generate broadly neutralizing antibodies that are likely necessary for protection. One vaccine candidate, eOD-GT8, was designed to bait naive B cells that may be capable of producing antibodies similar to VRC01, a potent CD4-binding site–targeting antibody with breadth. Havenar-Daughton et al. inspected the potential of human naive B cells to recognize eOD-GT8, and isolated B cells that used similar genes as those used to make VRC01. They also observed B cells with immunoglobulin genes similar to those used in other types of broadly neutralizing antibodies, some with a more conventional maturation path than VRC01. Their results suggest that vaccination of humans with eOD-GT8 has the potential to eventually induce CD4-binding site broadly neutralizing antibodies, which would be a major step forward in HIV vaccines.

View Full Text

Stay Connected to Science Translational Medicine